COMP <GO>
BRKR vs TXG // RSI-14 & 200D SMA MOMENTUM
Bruker Corporation (NASDAQ) VS. 10x Genomics Inc. (NASDAQ) • 15-METRIC TALLY: BRKR 6
— TXG 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: BRKR
LAST: $57.07 (-7.95%) • MKT CAP: $8.70B
rsi-technicals
45.8
LAST: $70.11 (-14.03%) • MKT CAP: $9.13B
rsi-technicals
45.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRKR VS. TXG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRKR | TXG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.90% | 69.10% | -23.20 | TXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.30% | -5.70% | +7.00 | BRKR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 75.7x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.46% | 1.22% | -0.76 | TXG | /fcf-yield <GO> |
| Operating Margin | 2.00% | -9.50% | +11.50 | BRKR | /operating-margins <GO> |
| Net Profit Margin | -0.20% | -6.80% | +6.60 | BRKR | /net-margins <GO> |
| Revenue Growth (YoY) | 2.10% | 5.20% | -3.10 | TXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 0.00% | +0.24 | BRKR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | 25.02 | -22.21 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 45.8 | 45.1 | +0.70 | BRKR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.15 | -0.18 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 24.0x | -2.00 | BRKR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.70B | $9.13B | -$439.6M | TXG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRKR REV | TXG REV | BRKR GROSS % | TXG GROSS % | BRKR FCF | TXG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.44B | $642.8M | 45.9% | 69.1% | $43.3M | $130.1M |
| FY 2024 | $3.37B | $610.8M | 49.0% | 67.9% | $136.0M | -$5.7M |
| FY 2023 | $2.96B | $618.7M | — | — | $216.7M | -$43.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRKR // BETA 0.97
TXG // BETA 1.15